Akgul, YurdanurPazar, ErdincYilmaz, HabibeLambrecht, Fatma YurtYilmaz, OsmanSanlier, Senay Hamarat2019-10-272019-10-2720150033-82300033-8230https://doi.org/10.1515/ract-2014-2304https://hdl.handle.net/11454/51930Crude extract of S. officinalis L. was found to have suspending agent, hemolytic, antitumor, antioxidant and antimicrobial activities. Its major components benzofurans and benzofuran glycosides have antifungal, anticancer, antibacterial and anticomplement activities and display acetylcholinesterase-cyclooxygenase inhibitory and cytotoxic properties. Recently, it has been reported that egonolgentiobioside is a valuable target for structural modification and warrants further investigation for its potential as a novel pharmaceutical tool for the prevention of estrogen deficiency induced diseases. The aim of the current study is to perform in vivo biological evaluation of a glycosides extract, which was isolated from the fruits endocarp of Styrax officinalis L, identified as egonolgentiobioside and homoegonolgentiobioside and labeled with I-131. The radiolabeled glycosides extract was labeled with I-131 with high yield. The labeled obtained radiolabeled compound was found to be quite stable and lipophilic. In order to determine its tissue distribution, an in vivo study was performed using healthy female Albino Wistar rats injected by I-131-glycosides. The biodistribution results showed that clearance of the radiolabeled compound is through the hepatobiliary pathway. The experimental study indicated that the radiolabeled glycosides extract accumulated in the large intestine. Therefore, the potential of I-131-glycosidesmight be evaluated in colon cancer cell lines and this might be a promising of tumor-imaging agent.en10.1515/ract-2014-2304info:eu-repo/semantics/closedAccessEgonol glycosidesI-131-glycosides-extractbiodistributionArticle1036457462WOS:000355624200006Q2